PeptideDB

IWP-2

CAS: 686770-61-6 F: C22H18N4O2S3 W: 466.60

IWP-2 (GMP) is IWP-2 (HY-13912) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity IWP-2 (GMP) is IWP-2 (HY-13912) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWP-2 is an inhibitor of Wnt processing and secretion with an IC50 of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and blocks Wnt ligand palmitoylation[1].
Target IC50: 27 nM (Wnt)
Invitro IWP-2 (GMP) (2 μM, in the first 4 days of Stage IV induction medium) reprograms human somatic cells to pluripotent stem cells[1].IWP-2 (GMP) (5 μM, day 3 to 5) induces cardiac differentiation of hiPSCs[2].IWP-2 (GMP) (5 μM, day 1 to 3) increasing the expression of cardiac progenitors and cardiac genes (MYL2, TNNI3, and TNNT2) in hiPSCs[3].IWP-2 (GMP) (5 μM, day 5-7) together with PIP-S2 induces cardiac mesoderm differentiates into functional cardiomyocytes[4].IWP-2 (GMP) (5 μM, treated at day 3) induces cardiomyocyte differentiation when applied following a pretreatment with Laduviglusib (GMP) (HY-10182G)[5]. RT-PCR[3] Cell Line:
Name IWP-2
CAS 686770-61-6
Formula C22H18N4O2S3
Molar Mass 466.60
Transport Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Reference [1]. Guan J et al. Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature. 2022;605(7909):325-331. [2]. Hamad S, et al. Generation of human induced pluripotent stem cell-derived cardiomyocytes in 2D monolayer and scalable 3D suspension bioreactor cultures with reduced batch-to-batch variations. Theranostics. 2019 Sep 25;9(24):7222-7238. [3]. Le MNT, et al. Auto/paracrine factors and early Wnt inhibition promote cardiomyocyte differentiation from human induced pluripotent stem cells at initial low cell density. Sci Rep. 2021 Nov 2;11(1):21426. [4]. Taniguchi J, et al. A synthetic DNA-binding inhibitor of SOX2 guides human induced pluripotent stem cells to differentiate into mesoderm. Nucleic Acids Res. 2017 Sep 19;45(16):9219-9228. [5]. Lian X, Zhang J, et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions. Nat Protoc. 2013 Jan;8(1):162-75.